The mechanisms underlying adaptive resistance of melanoma to targeted therapies remain unclear. By combining ChIP sequencing with microarray-based gene profiling, we determined that
Ethan V. Abel, Kevin J. Basile, Curtis H. Kugel III, Agnieszka K. Witkiewicz, Kaitlyn Le, Ravi K. Amaravadi, Giorgos C. Karakousis, Xiaowei Xu, Wei Xu, Lynn M. Schuchter, Jason B. Lee, Adam Ertel, Paolo Fortina, Andrew E. Aplin
Title and authors | Publication | Year |
---|---|---|
Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo
EJ Hartsough, CH Kugel, MJ Vido, AC Berger, TJ Purwin, A Goldberg, MA Davies, MJ Schiewer, KE Knudsen, G Bollag, AE Aplin |
Molecular cancer therapeutics | 2017 |
The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition
V Thakur, J Lu, G Roscilli, L Aurisicchio, M Cappelletti, E Pavoni, WL White, B Bedogni |
Oncotarget | 2017 |
Resistance mechanisms to genetic suppression of mutant NRAS in melanoma:
JP Robinson, VW Rebecca, DA Kircher, MR Silvis, I Smalley, GT Gibney, KJ Lastwika, G Chen, MA Davies, D Grossman, KS Smalley, SL Holmen, MW VanBrocklin |
Melanoma Research | 2017 |
Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas
CM Beltrami, MB Reis, MC Barros-Filho, FA Marchi, H Kuasne, CA Pinto, S Ambatipudi, Z Herceg, LP Kowalski, SR Rogatto |
Clinical Epigenetics | 2017 |
Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma
J Wouters, M Vizoso, A Martinez-Cardus, FJ Carmona, O Govaere, T Laguna, J Joseph, P Dynoodt, C Aura, M Foth, R Cloots, K Hurk, B Balint, IG Murphy, EW McDermott, K Sheahan, K Jirström, B Nodin, G Mallya-Udupi, JJ van Oord, WM Gallagher, M Esteller |
BMC Medicine | 2017 |
ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
D Alvarado, GF Ligon, JS Lillquist, SB Seibel, G Wallweber, VM Neumeister, DL Rimm, G McMahon, TM LaVallee, N Cordes |
PloS one | 2017 |
Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma
B Eskiocak, EA McMillan, S Mendiratta, RK Kollipara, H Zhang, CG Humphries, C Wang, J Garcia-Rodriguez, M Ding, A Zaman, TI Rosales, U Eskiocak, MP Smith, J Sudderth, K Komurov, RJ Deberardinis, C Wellbrock, MA Davies, JA Wargo, Y Yu, JK de Brabander, NS Williams, L Chin, H Rizos, GV Long, R Kittler, MA White |
Cancer Discovery | 2017 |
FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway
K Li, Q Guo, J Yang, H Chen, K Hu, J Zhao, X Pang, S Zhou, Y Dang, L Li |
Oncotarget | 2017 |
Overcoming resistance to BRAF inhibitors
I Arozarena, C Wellbrock |
Annals of translational medicine | 2017 |
Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation
N Suleymanova, C Crudden, C Worrall, A Dricu, A Girnita, L Girnita |
Oncotarget | 2017 |
FOXD3 Regulates CSC Marker, DCLK1-S, and Invasive Potential: Prognostic Implications in Colon Cancer
S Sarkar, MR O'Connell, Y Okugawa, BS Lee, Y Toiyama, M Kusunoki, RD Daboval, A Goel, P Singh |
Molecular cancer research : MCR | 2017 |
Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.
Fallahi-Sichani M, Becker V, Izar B, Baker GJ, Lin JR, Boswell SA, Shah P, Rotem A, Garraway LA, Sorger PK |
Molecular Systems Biology | 2017 |